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Expression of an oncogene in a primary cell can,
paradoxically, block proliferation by inducing senes-
cence or apoptosis through pathways that remain to
be elucidated. Here we perform genome-wide RNA-
interference screening to identify 17 genes required
for an activated BRAF oncogene (BRAFV600E) to
block proliferation of human primary fibroblasts and
melanocytes. Surprisingly, we find a secreted pro-
tein, IGFBP7, has a central role in BRAFV600E-medi-
ated senescence and apoptosis. Expression of
BRAFV600E in primary cells leads to synthesis and
secretion of IGFBP7, which acts through autocrine/
paracrine pathways to inhibit BRAF-MEK-ERK sig-
naling and induce senescence and apoptosis. Apo-
ptosis results from IGFBP7-mediated upregulation
of BNIP3L, a proapoptotic BCL2 family protein. Re-
combinant IGFBP7 (rIGFBP7) induces apoptosis in
BRAFV600E-positive human melanoma cell lines,
and systemically administered rIGFBP7 markedly
suppresses growth of BRAFV600E-positive tumors
in xenografted mice. Immunohistochemical analysis
of human skin, nevi, and melanoma samples impli-
cates loss of IGFBP7 expression as a critical step in
melanoma genesis.
INTRODUCTION
When expressed in primary cells, activated oncogenes can
block cellular proliferation by inducing senescence or apoptosis
(reviewed in Campisi, 2005; Mooi and Peeper, 2006). Oncogene-
induced senescence and apoptosis are thought to play impor-
tant roles in suppressing tumorigenesis by preventing prolifera-
tion of cells at risk for neoplastic transformation (Campisi,
2005; Michaloglou et al., 2005).
The BRAF proto-oncogene provides a paradigm for studying
oncogene-induced senescence and apoptosis. BRAF is a ser-
ine-threonine protein kinase that functions as an immediate
downstream effector of RAS (reviewed in Dhomen and Marais,2007). BRAF activates the MAP kinase extracellular signal regu-
lated kinase (MEK), which in turn phosphorylates and activates
extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2).
Activating BRAF mutations are found at high frequency in
human cancers and are particularly prevalent in melanoma where
they occur at a frequency of 50%–70% (Davies et al., 2002).
Approximately 90% of activating BRAF mutations are a glutamic
acid to valine substitution at position 600 (V600E; formally iden-
tified as V599E) (Davies et al., 2002). This mutation substantially
increases protein kinase activity, resulting in constitutive BRAF-
MEK-ERK signaling (Davies et al., 2002). In BRAFV600E-positive
melanoma cell lines and mouse xenografts, BRAFV600E has
been shown to be required for cell viability, proliferation, and
tumor growth (Hingorani et al., 2003; Hoeflich et al., 2006; Satya-
moorthy et al., 2003; Sharma et al., 2005).
Activating BRAF mutations are also present in up to 82% of
melanocytic nevi (Pollock et al., 2003), which are benign skin
lesions that rarely progress to melanoma (Bennett, 2003; Chin
et al., 1998). Nevi are growth arrested and display classical hall-
marks of senescence, including expression of senescence-
associated b-galactosidase and the cell-cycle inhibitor p16INK4a
(Michaloglou et al., 2005; Sparrow et al., 1998; Wang et al.,
1996). Expression of BRAFV600E also induces senescence in
cultured primary human melanocytes (Michaloglou et al., 2005).
How, then, does an activated BRAF oncogene induce uncon-
trolled proliferation in melanoma and senescence in benign nevi?
One hypothesis is that melanomas contain a second oncogenic
lesion that inactivates the BRAF-mediated senescence pathway
(reviewed in Campisi, 2005). Although attractive, this hypothesis
remains to be proven largely because the downstream factors
and signaling pathways involved in BRAF-mediated senescence
have not been characterized. Here we perform a genome-wide
RNA-interference (RNAi) screen to identify factors required for
BRAFV600E to block cellular proliferation.
RESULTS
A Genome-Wide shRNA Screen Identifies Factors
Required for BRAFV600E-Mediated Senescence
and Apoptosis
To identify genes required for BRAFV600E to block proliferation
of primary cells, we performed a genome-wide small hairpin RNACell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc. 363
Figure 1. A Genome-Wide shRNA Screen Identifies Factors Required for BRAFV600E-Mediated Senescence and Apoptosis
(A) Schematic summary of the genome-wide shRNA screen.
(B) Proliferation of the 17 BRAFV600E/PFF KD cell lines. 13 104 PFF fibroblasts stably expressing the indicated shRNA were cultured in 12-well plates, infected
with the BRAFV600E-expressing retrovirus, and after 14 days stained with crystal violet.
(C) Quantitative proliferation assays of the 17 BRAFV600E/melanocyte KD cell lines. Melanocytes stably expressing the indicated shRNA were infected with the
BRAFV600E-expressing retrovirus and after 14 days analyzed by trypan blue exclusion test. Growth of BRAFV600E/melanocytes is expressed relative to that of
normal melanocytes. Growth of BRAFV600E/melanocyte KD cell lines is normalized to that of the corresponding melanocyte KD cell line in the absence of
BRAFV600E expression. Error bars represent standard error.
(D) DNA replication assays of the 17 BRAFV600E/melanocyte KD cell lines, monitored by BrdU incorporation. Error bars represent standard error.
(E) Apoptosis assays of the 17 BRAFV600E/melanocyte KD cell lines, monitored by Annexin V-PE staining. Error bars represent standard error.
(F) Immunoblot analysis monitoring induction of p16INK4a and H3K9 acetylation in each of the 17 BRAFV600E/melanocyte KD cell lines. b-ACTIN (ACTB) was
monitored as a loading control.(shRNA) screen (Figure 1A). The primary screen was performed
in human primary foreskin fibroblasts (PFFs). A human shRNA
library comprising 62,400 shRNAs directed against 28,000
genes was divided into 10 pools, which were packaged into ret-
rovirus particles and used to stably transduce PFFs. The cells
were then infected with a retrovirus expressing BRAFV600E
under conditions in which all cells were infected. Cells that
bypassed the BRAFV600E-mediated cellular proliferation block
formed colonies, which were pooled and expanded, and the
shRNAs identified by sequence analysis. Positive candidates364 Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc.were confirmed by stable transduction of PFFs with single
shRNAs directed against the candidate genes, infection with
the BRAFV600E-expressing retrovirus, and quantitation of cellu-
lar proliferation. Confirmed candidate shRNAs were then tested
in a secondary screen for their ability to bypass the proliferation
block in BRAFV600E-expressing primary human melanocytes.
The screen identified 17 genes that, following shRNA-
mediated knockdown, enabled BRAFV600E-expressing PFFs
(BRAFV600E/PFFs) and melanocytes (BRAFV600E/melano-
cytes) to proliferate. These genes are listed in Table S1 (available
online), and proliferation assays of the 17 BRAFV600E/PFF
knockdown (KD) cell lines are shown in Figure 1B (for quantita-
tion, see Figure S1A). Expression of BRAFV600E in PFFs (data
not shown) or in PFFs containing a control nonsilencing (NS)
shRNA (Figure 1B) efficiently inhibited cellular proliferation.
Significantly, however, this block was overcome in all 17
BRAFV600E/PFF KD cell lines. Quantitative real-time RT-PCR
(qRT-PCR) confirmed in all cases that expression of the target
gene was decreased in the corresponding KD cell lines
(Figure S1B). For all 17 genes, a second, unrelated shRNA
directed against the same target gene also enabled PFFs to
proliferate following BRAFV600E expression (Figure S1C).
As expected from previous studies (Michaloglou et al.,
2005), expression of BRAFV600E in primary melanocytes effi-
ciently blocked cellular proliferation (Figure 1C). By contrast,
BRAFV600E failed to block cellular proliferation in all 17 melano-
cyte KD cell lines.
Following expression of BRAFV600E in melanocytes, the
majority of cells became senescent (Figure 1D and data not
shown), consistent with previous studies (Michaloglou et al.,
2005), although we found that 10% of cells underwent apopto-
sis (Figure 1E). To determine the role of the 17 genes in these two
pathways, apoptosis and senescence assays were performed in
each melanocyte KD cell line following BRAFV600E expression.
Figure 1E shows that only 3 of the 17 genes were required for
apoptosis: BNIP3L, which encodes a proapoptotic BCL2 family
protein; SMARCB1, which encodes a component of the SWI/
SNF chromatin-remodeling complex; and insulin growth factor
binding protein 7 (IGFBP7), which encodes a secreted protein
with weak homology to IGF-binding proteins. By contrast, all
but 1 of the 17 genes, BNIP3L, were required for BRAFV600E
to induce growth arrest (Figure 1D) and characteristic markers
of senescence (see below). Identical results were obtained using
BRAFV600E/melanocyte KD cell lines that had undergone an
additional 15 population doublings (Figure S2A) and in PFFs
(Figure S2B).
p16INK4a has been proposed to play an important role in
replicative and oncogene-induced senescence (reviewed in
Ben-Porath and Weinberg, 2005). We were therefore interested
in determining whether the genes identified in our screen were
required for p16INK4a induction. Figure 1F shows, as expec-
ted, that p16INK4a levels increased substantially following
BRAFV600E expression in control melanocytes expressing an
NS shRNA. Significantly, p16INK4a expression was not induced
by BRAFV600E in 16 of the 17 melanocyte KD cell lines. The
sole exception was the cell line knocked down for BNIP3L,
which, as described above, is specifically involved in apoptosis
(Figure 1F). Loss of histone H3 lysine 9 (H3K9) acetylation,
another well-characterized senescence marker (Narita et al.,
2006), also occurred following BRAFV600E expression in control
melanocytes but not in any of the melanocyte KD cell lines
except for the BNIP3L KD cell line (Figures 1F and S2A).
A Secreted Protein, IGFBP7, Induces Senescence
and Apoptosis through Autocrine/Paracrine Pathways
One of the genes required for the induction of both senescence
and apoptosis was IGFBP7, which encodes a secreted protein
(Wilson et al., 1997), raising the possibility that the BRAFV600E-mediated block to cellular proliferation might occur through an
autocrine/paracrine pathway. To determine whether IGFBP7 is
secreted and functions extracellularly, we analyzed the ability
of conditioned medium (CM) from BRAFV600E/melanocytes
to induce senescence. Figure 2A (top panel) shows that follow-
ing expression of BRAFV600E in melanocytes, the level of
IGFBP7 in CM increased substantially. Addition of CM from
BRAFV600E/melanocytes to naive melanocytes blocked cellular
proliferation, primarily resulting from the induction of senescence
(bottom panel and see Figure 2D below).
Two experiments verified that IGFBP7 activation was down-
stream of BRAF-MEK-ERK signaling. First, BRAFV600E-medi-
ated induction of IGFBP7 was blocked by addition of a MEK
inhibitor (Figure S3A). Second, expression of a constitutively
activated ERK mutant (ERK2Q103A or ERK2L73P,S151D) was
sufficient to activate IGFBP7 transcription (Figure S3B).
The IGFBP7 promoter contains a consensus binding site for
the dimeric AP-1 (JUN/FOS) transcription factor (Figure S4).
Significantly, JUN (also known as c-Jun) is activated through
RAF-MEK-ERK signaling (Leppa et al., 1998), raising the possi-
bility that AP-1 is involved in BRAFV600E-mediated induction
of IGFBP7. Chromatin immunoprecipitation (ChIP) analysis veri-
fied that JUN bound to the IGFBP7 promoter in response to
BRAFV600E expression (Figure S4A), and siRNA-mediated
knockdown of JUN abrogated induction of IGFBP7 transcription
in BRAFV600E/melanocytes (Figure S4B).
We next sought to verify that IGFBP7 was the secreted protein
responsible for the BRAFV600E-mediated cellular proliferation
block. In one experiment, we treated BRAFV600E/melanocytes
with an shRNA targeting IGFBP7. Figure 2A shows that IGFBP7
was absent from the CM of BRAFV600E/melanocytes express-
ing an IGFBP7 shRNA (top panel), and that this CM did not inhibit
cellular proliferation of naive melanocytes (bottom panel). In
a second experiment, immunodepletion with an a-IGFBP7
antibody efficiently removed IGFBP7 from CM of BRAFV600E/
melanocytes (top panel), and this immunodepleted CM failed
to inhibit cellular proliferation of naive melanocytes (bottom
panel).
To confirm that IGFBP7 could block cellular proliferation, we
purified recombinant IGFBP7 (rIGFBP7) from baculovirus-in-
fected insect cells. Figure 2B shows that following expression
and purification, a polypeptide of 33 kDa was detected, the
expected size of IGFBP7. Addition of rIGFBP7 blocked prolifer-
ation of primary melanocytes in a dose-dependent manner
(Figure 2C). The growth-arrested cells had an enlarged flat
morphology, characteristic of senescent cells, and stained pos-
itively for senescence-associated b-galactosidase (Figure 2D).
The finding that primary melanocytes expressed IGFBP7
(Figure 2A and see below) raised the possibility that under normal
conditions IGFBP7 might regulate melanocyte proliferation. To
test this idea, we compared the proliferation rates of untreated
melanocytes, control melanocytes expressing an NS shRNA,
and melanocytes expressing an IGFBP7 shRNA. Figure 2E
shows that melanocyte proliferation increased following IGFBP7
knockdown. Thus, normal melanocytes express low levels of
IGFBP7, which restrains proliferation. When present at high
levels, such as following expression of BRAFV600E, IGFBP7
induces senescence.Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc. 365
Figure 2. A Secreted Protein, IGFBP7, Induces Senescence and Apoptosis through Autocrine/Paracrine Pathways
(A) (Top) Immunoblot analysis of IGFBP7 levels in CM from normal melanocytes, BRAFV600E/melanocytes, BRAFV600E/melanocytes stably expressing an
IGFBP7 shRNA, or BRAFV600E/melanocyte CM treated with an a-IGFBP7 antibody. (Bottom) Proliferation assays on naive melanocytes following addition of
the different CMs described above. Proliferation was measured and normalized to the growth of untreated melanocytes. Error bars represent standard error.
(B) Coomassie-stained gel of purified, recombinant IGFBP7 (rIGFBP7). Molecular weight markers are shown on the left, in kDa.
(C) Proliferation assay monitoring the effect of rIGFBP7 on the growth of melanocytes 14 days after treatment. Error bars represent standard error.
(D) b-galactosidase staining of melanocytes infected with a retrovirus expressing either empty vector or BRAFV600E or melanocytes treated with CM from
BRAFV600E/melanocytes or rIGFBP7. Images are shown at a magnification of 103, 203, and 403.
(E) Proliferation assay monitoring growth rates of untreated melanocytes or melanocytes stably expressing an NS or IGFBP7 shRNA. Error bars represent
standard error.Selective Sensitivity of Melanoma Cell Lines
Containing an Activating BRAF Mutation
to IGFBP7-Mediated Apoptosis
We next analyzed the ability of IGFBP7 to block cellular
proliferation in a panel of human melanoma cell lines. The cells
contained either an activating BRAF mutation (BRAFV600E;
SK-MEL-28, MALME-3M, WM793B, WM39, and WM278) or an
activating RAS mutation (RASQ61R; SK-MEL-2, SK-MEL-103,
and WM1366) or were wild-type for both BRAF and RAS (CHL,
SK-MEL-31, WM1321, and WM3211). For each cell line, the
presence of IGFBP7 in the CM was determined by immunoblot
analysis (Figure 3A) and sensitivity to IGFBP7-induced growth
inhibition was measured in a proliferation assay (Figure 3B).
The results reveal a striking inverse correlation between IGFBP7
expression and sensitivity to IGFBP7-mediated growth inhibition
that correlates with the status of BRAF or RAS. Most importantly,
melanoma cell lines harboring an activating BRAF mutation fail to
express IGFBP7 and are highly sensitive to IGFBP7-mediated366 Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc.growth inhibition. By contrast, cells that are wild-type for BRAF
and RAS express IGFBP7 and are relatively insensitive to
IGFBP7-mediated growth inhibition. Finally, melanoma cell lines
containing an activating RAS mutation express low levels of
IGFBP7 and are partially sensitive to IGFBP7-mediated growth
inhibition. We further analyzed the IGFBP7-mediated cellular
proliferation block with regard to apoptosis and senescence.
Significantly, in melanoma cell lines harboring an activating
BRAF mutation, rIGFBP7 strongly induced apoptosis and surviv-
ing senescent cells were undetectable (Figure 3C and data not
shown). Thus, IGFBP7 primarily induced senescence in melano-
cytes and apoptosis in BRAFV600E-positive melanoma cells.
To understand the basis of this differential response, we
analyzed expression of the 17 genes in primary melanocytes
and SK-MEL-28 melanoma cells. Figure S5A (left panel) shows
that in primary melanocytes, expression of BRAFV600E resulted
in the transcriptional upregulation of seven genes, which are
involved in apoptosis (BNIP3L, IGFBP7, and SMARCB1) and
senescence (PEA15, IGFBP7, MEN1, FBXO31, SMARCB1, and
HSPA9). BRAFV600E-mediated induction of all seven genes did
not occur following knockdown of IGFBP7 (Figure S5B).
Following addition of rIGFBP7 to melanocytes, six of the seven
genes were induced, IGFBP7 being the exception (Figure S5A,
middle panel). Significantly, following addition of rIGFBP7 to
SK-MEL-28 cells, neither IGFBP7 nor PEA15 was upregulated
(Figure S5A, right panel). PEA15, a known regulator of BRAF-
MEK-ERK signaling (Formstecher et al., 2001), is required for
senescence (see Figure 1F). Thus, the lack of PEA15 induction
in IGFBP7-treated SK-MEL-28 cells can explain their failure to
undergo senescence. We note that BNIP3L is only modestly
upregulated in primary melanocytes following expression of
BRAFV600E or addition of rIGFBP7, consistent with the relatively
low level of apoptosis in IGFBP7-treated melanocytes (see
Figure 1E).
IGFBP7 Induces Apoptosis through Upregulation
of BNIP3L
As described above, BRAFV600E-mediated apoptosis was
dependent upon IGFBP7, SMARCB1, and BNIP3L, raising the
possibility that these three proteins were components of a com-
mon pathway required for apoptosis. We performed a series of
experiments to confirm this idea and establish the order of the
pathway. Figure 3D shows that following addition of rIGFBP7
to SK-MEL-28 cells, expression of SMARCB1 and BNIP3L
were significantly increased, and apoptosis occurred as evi-
denced by caspase 3 activation. Expression of a SMARCB1
shRNA blocked induction of BNIP3L and apoptosis. By contrast,
expression of a BNIP3L shRNA still resulted in induction of
SMARCB1 following rIGFBP7 addition although apoptosis did
not occur. Collectively, these results reveal a pathway in which
IGFBP7 increases expression of SMARCB1, which in turn leads
to increased expression of BNIP3L culminating in apoptosis
(Figure 3D, bottom panel).
In BRAFV600E/melanocytes, induction of SMARCB1 and
BNIP3L was blocked following IGFBP7 knockdown (Figure S6A).
Moreover, addition of CM from BRAFV600E-expressing melano-
cytes to naive melanocytes substantially upregulated SMARCB1
and BNIP3L, which did not occur with various control CMs that
lacked IGFBP7 (Figure S6B). Thus, in BRAFV600E/melanocytes
induction of SMARCB1 and BNIP3L is also dependent upon and
downstream of IGFBP7.
We next sought to determine the mechanistic basis for
IGFBP7-mediated induction of BNIP3L and SMARCB1. A pre-
vious study analyzing genome-wide targets of STAT proteins
had provided evidence that STAT1 was involved in certain
SMARCB1-inducible transcription responses and had shown
that the SMARCB1 promoter contains a STAT1 binding site
located 2.4 kb upstream of the transcription start site (Hartman
et al., 2005). We therefore investigated the potential role of
STAT1 in IGFBP7-mediated induction of SMARCB1 transcrip-
tion. ChIP experiments revealed that following addition of
rIGFBP7 to SK-MEL-28 cells, STAT1 was recruited to the
SMARCB1 promoter (Figure 3E), and shRNA-mediated knock-
down experiments confirmed that STAT1 was required for
IGFBP7-mediated upregulation of SMARCB1 (Figure 3F).As described above, SMARCB1 is required for upregulation of
BNIP3L by IGFBP7 (Figure 3D). ChIP experiments revealed that
following addition of rIGFBP7, SMARCB1 as well as BRG1, an
essential subunit of the SWI/SNF complex (Bultman et al.,
2000), were recruited to the BNIP3L promoter near the transcrip-
tion start site (Figure 3G). Following knockdown of SMARCB1,
BRG1 (and, as expected, SMARCB1) failed to associate with
the BNIP3L promoter. Collectively, these results indicate that
IGFBP7 stimulates BNIP3L transcription, at least in part, by
increasing intracellular levels of SMARCB1, leading to formation
of a SMARCB1-containing SWI/SNF chromatin-remodeling
complex, which is recruited to the BNIP3L promoter and facili-
tates BNIP3L transcriptional activation.
Finally, we asked whether apoptosis was dependent upon the
continual presence of rIGFBP7 or was irreversible following
transient exposure to rIGFBP7. SK-MEL-28 cells were incubated
with rIGFBP7 for various lengths of time, following which the cells
were washed and cultured in medium lacking rIGFBP7, and
apoptosis was quantitated after 24 hr. Figure 3H shows that
following 6 hr of incubation with rIGFBP7, the cells were irrevers-
ibly committed to apoptosis, which occurred even after removal
of rIGFBP7.
IGFBP7 Inhibits BRAF-MEK-ERK Signaling
In BRAFV600E-positive melanoma cells BRAF-MEK-ERK signal-
ing is hyperactivated, rendering the cells highly dependent on
this pathway. Thus, treatment of BRAFV600E-positive mela-
noma cells with a BRAF shRNA (Hoeflich et al., 2006) or an inhib-
itor of BRAF (Sharma et al., 2005) or MEK (Solit et al., 2006)
blocks cellular proliferation. We therefore considered the possi-
bility that IGFBP7 blocks cellular proliferation, at least in part, by
inhibiting BRAF-MEK-ERK signaling.
To test this idea we added rIGFBP7 to SK-MEL-28 cells and
analyzed the levels of total and activated ERK (phospho-ERK).
Figure 4A shows that addition of rIGFBP7 resulted in a
dose-dependent loss of phospho-ERK. Similarly, expression of
BRAFV600E in melanocytes markedly decreased phospho-
ERK levels, which did not occur in BRAFV600E/melanocytes
expressing an IGFBP7 shRNA (Figure S7A). Moreover, addition
of CM from BRAFV600E/melanocytes to naive melanocytes
substantially decreased the levels of phospho-ERK, which did
not occur with various control CMs that lacked IGFBP7
(Figure S7B). rIGFBP7 also blocked growth factor-induced
ERK activation (Figure S7C). Collectively, these results indicate
that IGFBP7 inhibits BRAF-MEK-ERK signaling.
Addition of rIGFBP7 to SK-MEL-28 cells resulted in decreased
levels of activated MEK1/2, corresponding with the reduced
phospho-ERK levels and increased apoptosis (Figure S8A).
Moreover, ectopic expression of a constitutively activated
MEK1 mutant (MEK1-EE) prevented IGFBP7 from blocking
ERK activation (Figure S8B). These results demonstrate that
IGFBP7 blocks phosphorylation of MEK by BRAF. Finally, we
found that addition of IGFBP7 to SK-MEL-28 cells resulted in up-
regulation of RAF inhibitory protein (RKIP) (Figures S8A and
S8C), which has been shown to interact with several RAF pro-
teins, including BRAF, and inhibit RAF-mediated phosphoryla-
tion of MEK (see, for example, Park et al., 2005). Following
knockdown of RKIP in SK-MEL-28 cells, rIGFBP7 failed to blockCell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc. 367
Figure 3. Selective Sensitivity of Melanoma Cell Lines Containing an Activating BRAF Mutation to IGFBP7-Mediated Apoptosis
(A) (Top) Immunoblot analysis monitoring IGFBP7 levels in the CM from a panel of human melanoma cell lines. (Bottom) Quantitative real-time RT-PCR analysis of
IGFBP7 expression. Error bars represent standard error.
(B) Proliferation assays of human melanoma cell lines 24 hr after rIGFBP7 treatment. Proliferation was normalized to the growth of the corresponding cell line in the
absence of rIGFBP7 addition. Error bars represent standard error.
(C) Apoptosis assays of human melanoma cell lines treated with rIGFBP7. Error bars represent standard error.
(D) (Top) Immunoblot analysis in SK-MEL-28 cells in the presence or absence of rIGFBP7 and stably expressing either an NS, SMARCB1, or BNIP3L shRNA.
(Bottom) Schematic summary of the IGFBP7-mediated apoptotic pathway.
(E) ChIP analysis monitoring STAT1 recruitment to the SMARCB1 promoter in SK-MEL-28 cells. Error bars represent standard error.
(F) qRT-PCR analysis of SMARCB1 (left) or STAT1 (right) mRNA levels in SK-MEL-28 cells following treatment with an NS or STAT1 siRNA. Error bars represent
standard error.
(G) ChIP analysis monitoring SMARCB1 (left) or BRG1 (right) recruitment to the BNIP3L promoter in SK-MEL-28 cells. Error bars represent standard error.
(H) SK-MEL-28 cells were incubated with rIGFBP7 for 0, 2, 6, 12, or 24 hr, following which the cells were washed and cultured in medium lacking rIGFBP7 and
apoptosis was quantitated.activation of MEK or ERK (Figure S8C). Collectively, these results
indicate that IGFBP7 inhibits BRAF-MEK-ERK signaling by in-
ducing RKIP, which prevents BRAF from phosphorylating MEK.
To establish the relationship between inhibition of
BRAF-MEK-ERK signaling and the IGFBP7-mediated block to
cellular proliferation, we ectopically expressed a constitutively368 Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc.activated ERK2 or MEK1 mutant and analyzed sensitivity to
rIGFBP7. Figure 4B shows that expression of either an ERK2
(left) or MEK1 (right) mutant in SK-MEL-28 cells substantially
overcame the IGFBP7-mediated cellular proliferation block.
Expression of a constitutively activated ERK2 mutant also
blocked BRAFV600E- and IGFBP7-induced senescence in
melanocytes (Figure S9). In addition, ectopic expression of
a constitutively activated ERK2 mutant in SK-MEL-28 cells
increased phospho-ERK2 levels and prevented the IGFBP7-
mediated upregulation of BNIP3L and induction of apoptosis
(Figure 4C).
The above results allowed us to draw two conclusions. First,
IGFBP7 blocks cellular proliferation, at least in part, by inhibiting
BRAF-MEK-ERK signaling. Second, inhibition of BRAF-MEK-
ERK signaling is required for activation of the IGFBP7-
mediated apoptotic pathway. This latter observation prompted
us to ask whether inhibition of BRAF-MEK-ERK signaling was
sufficient to induce apoptosis. Figure 4D shows, as expected,
that addition of a MEK or RAF inhibitor blocked BRAF-MEK-
ERK signaling. However, unlike rIGFBP7, MEK and RAF inhibi-
tors did not increase BNIP3L levels or efficiently induce apopto-
sis. Thus, inhibition of BRAF-MEK-ERK signaling is necessary
but not sufficient for IGFBP7-mediated upregulation of BNIP3L
and induction of apoptosis.
IGFBP7 Suppresses Growth of BRAFV600E-Positive
Tumors in Xenografted Mice
The ability of IGFBP7 to inhibit proliferation of BRAFV600E-
positive human melanoma cell lines (see Figure 3B) raised the
possibility that IGFBP7 could suppress growth of tumors con-
Figure 4. IGFBP7 Blocks BRAF-MEK-ERK
Signaling to Activate the Apoptotic Pathway
(A) Immunoblot analysis in SK-MEL-28 cells
treated with increasing concentrations of rIGFBP7
(0.2, 1.0, 2.0, 5.0, or 10 mg/ml) for 24 hr.
(B) Proliferation assays monitoring sensitivity of
SK-MEL-28 cells to rIGFBP7. Cells were trans-
fected with an empty expression vector or a con-
stitutively activated ERK2 or MEK1 mutant. Cell
growth was analyzed 24 hr after treatment with
rIGFBP7 and normalized to the growth of the cor-
responding cell line in the absence of rIGFBP7 ad-
dition. Error bars represent standard error.
(C) Immunoblot analysis in SK-MEL-28 cells stably
transfected with an empty expression vector or
a constitutively activated ERK2 mutant. SK-MEL-
28 cells were either untreated or treated with
10 mg/ml of rIGFBP7, as indicated, for 24 hr prior
to harvesting cells.
(D) Immunoblot analysis in SK-MEL-28 cells 24 hr
after treatment with rIGFBP, a MEK inhibitor
(MEK-i), or a RAF inhibitor (RAF-i).
taining an activating BRAF mutation. As
a first test of this possibility, human mela-
noma cells that contained (SK-MEL-28)
or lacked (SK-MEL-31) an activating
BRAF mutation were injected subcutane-
ously into the flanks of nude mice. Three,
six, and nine days later, the mice were in-
jected at the tumor site with either
rIGFBP7 or, as a control, PBS. Figure 5A
shows that rIGFBP7 substantially sup-
pressed growth of BRAFV600E-positive
tumors but had no effect on tumors containing wild-type BRAF.
We next asked whether tumor growth could also be sup-
pressed by systemic administration of rIGFBP7. SK-MEL-28 or
SK-MEL-31 cells were injected into the flanks of nude mice
and when tumors reached a size of 100 mm3, 100 mg rIGFBP7
was delivered by tail vein injection at days 6, 9, and 12.
Figure 5B shows that systemic administration of rIGFBP7 com-
pletely suppressed growth of BRAFV600E-positive tumors,
whereas tumors containing wild-type BRAF were unaffected.
In mice treated with rIGFBP7, BRAFV600E-positive tumors
were deoxyuridine triphosphate nick-end labeling (TUNEL) pos-
itive (Figure S10), indicating that suppression of tumor growth
resulted from apoptosis. Suppression of tumor growth by sys-
temically administered rIGFBP7 was dose dependent, and con-
centrations higher than that required for inhibition of tumor
growth could be delivered without apparent adverse effects
(Figure 5C and data not shown).
Loss of IGFBP7 Expression Is a Critical Step
in Development of a BRAFV600E-Positive Melanoma
As shown above, BRAFV600E-positive melanoma cell lines fail
to express IGFBP7 and are highly sensitive to IGFBP7-mediated
apoptosis. These results raised the possibility that IGFBP7 func-
tions as a tumor suppressor and loss of IGFBP7 might beCell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc. 369
required for development of BRAFV600E-positive melanoma. To
investigate this possibility, we performed immunohistochemical
analysis of IGFBP7 expression on a series of human skin, nevi,
and melanoma samples.
Figure 6 and Table S2 show that normal skin melanocytes
expressed low but detectable levels of IGFBP7. BRAFV600E-
positive nevi expressed high levels of IGFBP7, consistent with
the finding that expression of BRAFV600E in melanocytes in-
Figure 5. IGFBP7 Suppresses Growth of BRAFV600E-Positive
Tumors in Xenografted Mice
(A) SK-MEL-28 or SK-MEL-31 cells were injected subcutaneously into the
flanks of nude mice, and 3, 6, and 9 days later (denoted by arrows), the
mice were injected at the tumor site with rIGBP7 or, as a control, PBS. Error
bars represent standard error.
(B) SK-MEL-28 or SK-MEL-31 cells were injected into the flanks of nude mice.
When tumors reached a size of 100 mm3, 100 mg rIGFBP7 was systemically
administered by tail vein injection at days 6, 9, and 12 (indicated by arrows).
Error bars represent standard error.
(C) Dose-dependent suppression of tumor growth by rIGFBP7. SK-MEL-28
cells were injected into the flanks of nude mice as described in (B), following
which rIGFBP7 was systemically administered by tail vein injection. Tumor
volume was measured at day 21. Error bars represent standard error.370 Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc.creased IGFBP7 levels (Figure 2A). Significantly, expression of
IGFBP7 was not detectable in BRAFV600E-positive melanomas.
By contrast, IGFBP7 was clearly expressed in melanomas lack-
ing activated BRAF.
To determine whether loss of IGFBP7 expression was the
result of epigenetic silencing, we performed bisulfite sequence
analysis. Figure 7A shows that the IGFBP7promoter was densely
hypermethylated in BRAFV600E-positive melanomas but not in
BRAFV600E-positive nevi or melanomas lacking activated
BRAF. Similar analyses in a panel of melanoma cell lines showed
that the IGFBP7 promoter was densely hypermethylated in
BRAFV600E-positive melanoma cell lines and modestly hy-
permethylated in NRASQ61R-positive melanoma cell lines (Fig-
ure 7B). Treatment of these cell lines with the DNA methyltrans-
ferase inhibitor 5-aza-20-deoxycytidine restored IGFBP7
expression in BRAFV600E- and NRASQ61R-positive cell lines
but had no effect in BRAF/RAS wild-type cell lines (Figure 7C).
Collectively, these results indicate that loss of IGFBP7 expres-
sion in BRAFV600E-positive melanomas and cell lines results
from epigenetic silencing involving promoter hypermethylation.
DISCUSSION
By performing a genome-wide shRNA screen, we have identified
17 genes that are essential for BRAFV600E to induce senes-
cence or apoptosis in primary cells. Unexpectedly, a critical
component of the senescence and apoptotic pathways is a se-
creted protein, IGFBP7. Expression of BRAFV600E in primary
cells induces synthesis and secretion of IGFBP7, which func-
tions through autocrine/paracrine pathways to inhibit BRAF-
MEK-ERK signaling and induce senescence or apoptosis. Con-
sistent with our findings are previous reports that IGFBP7 (also
called IGFBP-rP1 or MAC25) can inhibit proliferation of some
cancer cell lines in vitro (see, for example, Hingorani et al.,
2003; Mutaguchi et al., 2003; Ruan et al., 2006; Swisshelm
et al., 1995; Wilson et al., 2002). Our results provide new insights
into how activated BRAF promotes senescence, apoptosis and
malignant transformation, which are schematically summarized
in Figure 7D and discussed below.
We note that TP53 was one of the genes we identified as
required for BRAFV600E-mediated senescence. There have
been several previous reports that loss of TP53 does not enable
escape from oncogene-induced senescence (see, for example,
Beausejour et al., 2003; Narita et al., 2006; Zhu et al., 1998).
However, these studies involved either a different cell type or
oncogene than those used here.
Activated BRAF-Mediated Senescence
Occurs through an Autocrine/Paracrine Pathway
that Establishes a Negative Feedback Loop
Previous studies have shown that expression of BRAFV600E in
melanocytes results in an initial proliferative burst leading to
clonal expansion followed by growth arrest (Michaloglou et al.,
2005). Our results explain this biphasic response. In the first
phase, the initial expression of BRAFV600E increases BRAF-
MEK-ERK signaling, providing a transient proliferative signal. In
the second phase, BRAFV600E expression results in the synthe-
sis and secretion of IGFBP7, which acts through an autocrine/
Figure 6. Loss of IGFBP7 Expression Is a Critical Step in Development of a BRAFV600E-Positive Melanoma
Immunohistochemical analysis of IGFBP7 expression in human tissue samples. Samples were stained with hematoxylin and eosin (H&E). Arrowheads indicate
IGFBP7-positive melanocytes. Images are shown at 23 and/or 203.paracrine pathway to inhibit BRAF-MEK-ERK signaling and
activate a senescence program.
The nonuniform expression of p16INK4a in nevi has prompted
speculation that senescent cells secrete a senescence-inducing
agent that acts upon neighboring cells (Gray-Schopfer et al.,
2007). We find that BRAFV600E-positive melanocytic nevi ex-
press high levels of IGFBP7 and propose that secreted IGFBP7
has a central role in the initiation and maintenance of the senes-
cent state. A senescence-inducing secreted protein provides
a powerful mechanism for tumor suppression because, following
an initial oncogenic event in a single cell, neighboring cells are
also protected.
Role for IGFBP7 inMelanoma Development and Therapy
BRAFV600E cannot fully transform human melanocytes, imply-
ing the existence of additional, cooperating events required for
tumor development (Peeper and Mooi, 2002). The 17 genes we
have identified are potential tumor suppressors in malignancies
involving an activating BRAF mutation. Unlike nevi, BRAFV600E-
positive melanomas do not express IGFBP7. On the basis of this
observation and the other results presented in this study, we
propose that loss of IGFBP7 expression allows escape from
BRAFV600E-mediated senescence and is a critical step in
melanoma genesis.
Activated BRAF-positive metastatic melanoma is an aggres-
sive disease that is refractory to conventional chemotherapeutic
agents and lacks adequate treatment options (reviewed in Gray-
Schopfer et al., 2007). Inhibitors of BRAF have been developed
but unfortunately have performed poorly in clinical trials. We
have shown that IGFBP7, but not a RAF or MEK inhibitor,
efficiently induces apoptosis in BRAFV600E-positive melanoma
cell lines. IGFBP7 may be a more efficacious anticancer agent
than a BRAF or MEK inhibitor because it both inhibits BRAF-
MEK-ERK signaling and irreversibly induces apoptosis following
transient exposure. The selective sensitivity of BRAFV600E-
containing human cancer cell lines to IGFBP7, and the ability
of IGFBP7 to suppress BRAFV600E-positive tumor growth inmice, suggest that IGFBP7 may have a role in treating malignan-
cies harboring activating BRAF mutations.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture
Primary foreskin fibroblasts (BJ) and human melanoma cell lines were
obtained from ATCC, and human primary melanocytes were obtained from
Cascade Biologics; all cells were grown as recommended by the supplier.
Retroviruses and Plasmids
Retroviruses expressing empty vector or BRAFV600E were generated from
plasmids pBABE-zeo (Addgene) or pBABE-zeo/BRAFV600E (Michaloglou
et al., 2005), respectively. Plasmids expressing ERK2Q103A and ERK2L73P,
S151D (Emrick et al., 2006) and MEK1EE (Tournier et al., 1999) have been de-
scribed.
shRNA Screen
The human shRNAmir library (release 1.20; Open Biosystems) was obtained
through the UMass Medical School shRNA library core facility. Retroviral pools
were generated and used to transduce PFFs as described (Gazin et al., 2007).
Cells were then infected with a retrovirus carrying BRAFV600E at MOI 20. Cells
that bypassed the BRAFV600E-induced cellular proliferation block formed col-
onies, which were pooled and expanded, and the shRNAs identified by
sequence analysis as previously described (Gazin et al., 2007). Individual
knockdown cell lines were generated by stable transduction of 6 3 104 cells
with a single shRNA followed by infection with the BRAFV600E-expressing
retrovirus. Individual shRNAs were either obtained from the Open Biosystems
library or synthesized (see Table S3).
Quantitative Real-Time RT-PCR
Total RNA was isolated and reverse transcription was performed as described
(Gazin et al., 2007), followed by quantitative real-time PCR using Platinum
SYBR Green qPCR SuperMix-UDG with Rox (Invitrogen). Primer sequences
are provided in Table S4.
Quantitative Proliferation Assay
Cell viability was measured by trypan blue exclusion at the time point indicated
in the relevant figure legend. The number of viable cells was quantitated, and the
values were expressed as percent cell growth, as described in the relevant fig-
ure legend. For the assay shown in Figure 2A, CM was replenished every 3 days
and proliferation was measured after a total of 14 days of CM treatment. Unless
otherwise stated, rIGFBP7 was added to the culture medium at 10 mg/ml.Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc. 371
Figure 7. The IGFBP7 Promoter Is Hypermethylated in BRAFV600E-Positive Melanoma Cell Lines and Tissues
(A) Bisulfite sequence analysis of the IGFBP7 promoter in human tissue samples. (Top) Schematic of the IGFBP7 promoter; positions of the CpG dinucleotides are
shown to scale by vertical lines. (Bottom) Each circle represents a CpG dinucleotide: open (white) circles denote unmethylated CpG sites and filled (black) circles
indicate methylated CpG sites. Each row represents a single clone.
(B) Bisulfite sequence analysis of the IGFBP7 promoter in a panel of melanoma cell lines.
(C) qRT-PCR analysis of IGFBP7mRNA levels in melanoma cell lines following treatment with the DNA methyltransferase inhibitor 5-aza-20-deoxycytidine (5-aza).
Error bars represent standard error.
(D) Schematic summary of BRAFV600E-mediated senescence and melanoma progression. Normal melanocytes (BRAF-wt) express and secrete low levels of
IGFBP7, which inhibits BRAF-MEK-ERK signaling through an autocrine/paracrine pathway, thereby restraining proliferation. In BRAFV600E-positive nevi,
constitutive activation of the BRAF-MEK-ERK pathway increases expression and secretion of IGFBP7, and the resultant high levels of IGFBP7 inhibit BRAF-
MEK-ERK signaling and activate senescence. In a BRAFV600E-positive melanoma, IGFBP7 expression is lost, enabling the cells to escape from senescence
and resulting in uncontrolled proliferation. Addition of exogenous IGFBP7 to BRAFV600E-positive melanoma cells inhibits BRAF-MEK-ERK signaling and
activates apoptosis.372 Cell 132, 363–374, February 8, 2008 ª2008 Elsevier Inc.
Apoptosis and DNA Replication Assays
PFFs, melanocytes, or shRNA knockdown derivatives (5 3 105 cells) were
infected with BRAFV600E-expressing retrovirus, and 4 days later the total
cell population was stained for Annexin V-PE (BD Biosciences). To monitor
apoptosis in melanoma cells following rIGFBP7 treatment, 5 3 105 cells
were treated with rIGFBP7 (10 mg/ml) for 24 hr and stained for Annexin
V-PE. For DNA replication assays, cells were treated as described above,
except 4 hr prior to the end of the 4 day retroviral infection, cells were incu-
bated with 20 mM BrdU (Sigma) and processed as previously described
(Wajapeyee and Somasundaram, 2003).
Antibodies and Immunoblot Analysis
Cell extracts were prepared by lysis in Laemmli buffer in the presence or
absence of a phosphatase inhibitor cocktail (Sigma), as needed. To prepare
CM, cells were grown in Opti-MEM (Invitrogen) for 24 hr and media were har-
vested and concentrated using Centricon plus 20 tubes (Millipore). CM was
normalized to cell number prior to loading the gel. For the experiments shown
in Figures 3E and 4C, rIGFBP7 was added to the culture medium at 10 mg/ml.
For the experiment of Figure 4D, SK-MEL-28 cells were treated with 2 mg/ml or
10 mg/ml rIGFBP7, 20 mM or 40 mM of the MEK inhibitor PD98054 (Calbio-
chem), or 5 nM or 10 nM of the RAF inhibitor GW5074 (Sigma) for 24 hr prior
to harvesting cells. Blots were probed with the following antibodies: a-p16
(Abcam); a-acetylated H3K9 (Upstate); a-IGFBP7, a-BRAFV600E, cleaved
caspase-3 p11 (Santa Cruz); a-SMARCB1 (Abnova); a-BNIP3L (Proscience);
a-b-actin (Sigma); or a-phospho-ERK or a-ERK (Cell Signaling Technology).
Recombinant IGFBP7 Expression and Purification
The human IGFBP7 expression vector pFASTBAC-1/IGFBP7, expressing
a C-terminal Flag-tagged fusion protein (Oh et al., 1996), was used to generate
recombinant baculovirus using the Bac-to-Bac Baculovirus Expression
System (Invitrogen). The recombinant baculovirus construct was then trans-
fected into Sf9 cells (Invitrogen), and CM was collected and incubated with
a-Flag M2 beads (Sigma), and the bound IGFBP7 protein was eluted using
an a-Flag peptide (synthesized by CFAR, UMass Medical School, USA).
Senescence-Associated b-galactosidase Assay
Melanocytes infected with a retrovirus expressing either vector or BRAFV600E
or melanocytes treated with BRAFV600E/melanocyte CM or rIGFBP7 (10mg/ml)
for 14 days were processed as previously described (Dimri et al., 1995). Cells
were visualized on a Zeiss Axiovert 40 CFL microscope. Images were captured
using QCapture Pro version 5 software (QImaging Corporation).
ChIP Assays
ChIP assays were performed using extracts prepared 24 hr following rIGFBP7
treatment. The following antibodies were used: a-BRG1 (a gift from A. Imbal-
zano, UMass Medical School), a-phospho-STAT1 (Upstate), and a-SMARCB1
and a-STAT1 (Santa Cruz). For ChIP experiments on the SMARCB1 promoter,
primers spanning a STAT1 binding site located 2.4 kb upstream of the tran-
scription start site were used. For ChIP experiments on the BNIP3L promoter,
a series of primer pairs that covered 2 kb of theBNIP3L promoter were used;
following addition of rIGFBP7, SMARCB1 and BRG1 were recruited to the
BNIP3L promoter near the transcription start site. shRNA/siRNA sequences
are provided in Table S3, and primer sequences used for amplifying the
ChIP products are provided in Table S4. ChIP products were analyzed by
quantitative real-time PCR using Platinum SYBR Green qPCR SuperMix-
UDG with Rox (Invitrogen). Calculation of fold-differences was done as previ-
ously described (Pfaffl, 2001).
Tumor Formation Assays
5 3 106 SK-MEL-28 or SK-MEL-31 cells were suspended in 100 ml of serum-
free DMEM and injected subcutaneously into the right flank of athymic Balb/c
(nu/nu) mice (Taconic). At days 3, 6, and 9, mice were injected at the tumor site
with either rIGBP7 (20 mg in 100 ml total volume) or, as a control, PBS. Tumor
dimensions were measured every three days and tumor volume was calcu-
lated using the formula p/63 (length)3 (width)2. For the systemic administra-
tion experiments, cells were injected into the flank as described above and
when tumors reached a size of 100 mm3, 100 mg rIGFBP7 in a total volumeof 100 ml was delivered by tail vein injection at days 6, 9, and 12. Tumor dimen-
sions were measured every 3 days. Animal experiments were performed in
accordance with the Institutional Animal Care and Use Committee (IACUC)
guidelines.
Immunohistochemistry
The study was approved by the UMass Medical Center institutional review
board (IRB #12543). Archival materials from normal skin (n = 5), nevi (n = 20),
and malignant melanoma (primary [n = 7] and metastatic [n = 13]) were
retrieved from the pathology files of UMass Medical Center, Worcester, MA.
The histologic sections of all cases were re-reviewed and the diagnoses
confirmed by a dermatopathologist (MM). All patient data were de-identified.
Five micrometer-thick sections were cut for immunohistochemical studies,
which were performed, using standard techniques, with heat-induced epitope
retrieval buffer and an a-IGFBP7 antibody (1:20 dilution; Santa Cruz). Appro-
priate positive and negative controls were included. Positive staining was
noted by ascertaining expression of IGFBP7 in the cytoplasm; significant
nuclear staining was not noted. All stained slides were reviewed by the derma-
topathologist (MM) in a blind fashion with respect to genotype. Genomic DNA
was isolated and quantitated, followed by PCR amplification (see Table S4 for
primer sequences) and TA cloning (Promega). Multiple clones were sequenced
for identifying the V600E mutation (T1796A) in exon 15 of the BRAF gene.
Bisulfite Sequencing
Bisulfite modification was carried out essentially as described (Frommer et al.,
1992) except that hydroquinone was used at a concentration of 125 mM during
bisulfite treatment (carried out in the dark) and DNA was desalted on Qiaquick
columns (QIAGEN) after the bisulfite reaction. Six clones were sequenced for
each cell line or human tissue sample (see Table S4 for primer sequences). For
5-aza-20-deoxycytidine (5-aza) treatment, melanoma cell lines were treated
with 10 mM 5-aza (Calbiochem) for 48 hr.
Supplemental Data
Supplemental Data include Experimental Procedures, ten figures, and four
tables and can be found with this article online at http://www.cell.com/cgi/
content/full/132/3/363/DC1/.
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